ADMA BIOLOGICS INC (ADMA) Fundamental Analysis & Valuation

NASDAQ:ADMA • US0008991046

Current stock price

10.52 USD
+0.27 (+2.63%)
At close:
10.63 USD
+0.11 (+1.05%)
Pre-Market:

This ADMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. ADMA Profitability Analysis

1.1 Basic Checks

  • In the past year ADMA was profitable.
  • In the past year ADMA had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ADMA reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • ADMA has a Return On Assets of 23.54%. This is amongst the best in the industry. ADMA outperforms 96.28% of its industry peers.
  • ADMA has a Return On Equity of 30.78%. This is amongst the best in the industry. ADMA outperforms 96.48% of its industry peers.
  • ADMA has a better Return On Invested Capital (27.76%) than 98.83% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ADMA is significantly below the industry average of 28.47%.
  • The 3 year average ROIC (20.20%) for ADMA is below the current ROIC(27.76%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROIC 27.76%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Profit Margin of ADMA (28.80%) is better than 93.93% of its industry peers.
  • Looking at the Operating Margin, with a value of 37.52%, ADMA belongs to the top of the industry, outperforming 96.67% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 57.39%, ADMA is in the better half of the industry, outperforming 76.13% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ADMA has grown nicely.
Industry RankSector Rank
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ADMA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
  • ADMA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ADMA has been increased compared to 5 years ago.
  • ADMA has a better debt/assets ratio than last year.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • ADMA has an Altman-Z score of 12.46. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 12.46, ADMA belongs to the best of the industry, outperforming 84.15% of the companies in the same industry.
  • ADMA has a debt to FCF ratio of 2.62. This is a good value and a sign of high solvency as ADMA would need 2.62 years to pay back of all of its debts.
  • ADMA's Debt to FCF ratio of 2.62 is amongst the best of the industry. ADMA outperforms 93.15% of its industry peers.
  • ADMA has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.15, ADMA is not doing good in the industry: 65.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Altman-Z 12.46
ROIC/WACC2.9
WACC9.58%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • ADMA has a Current Ratio of 6.71. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 6.71, ADMA is in the better half of the industry, outperforming 65.75% of the companies in the same industry.
  • A Quick Ratio of 3.74 indicates that ADMA has no problem at all paying its short term obligations.
  • ADMA has a Quick ratio of 3.74. This is comparable to the rest of the industry: ADMA outperforms 48.34% of its industry peers.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 3.74
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ADMA Growth Analysis

3.1 Past

  • ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite good.
  • ADMA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.63%.
  • ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 64.62% yearly.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%

3.2 Future

  • ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.88% yearly.
  • Based on estimates for the next years, ADMA will show a quite strong growth in Revenue. The Revenue will grow by 19.04% on average per year.
EPS Next Y62.35%
EPS Next 2Y43.82%
EPS Next 3Y40.03%
EPS Next 5Y33.88%
Revenue Next Year24.85%
Revenue Next 2Y23.47%
Revenue Next 3Y22.77%
Revenue Next 5Y19.04%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

8

4. ADMA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 17.53 indicates a rather expensive valuation of ADMA.
  • Compared to the rest of the industry, the Price/Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.93% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.51. ADMA is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 10.80, which indicates a very decent valuation of ADMA.
  • ADMA's Price/Forward Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 97.85% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of ADMA to the average of the S&P500 Index (21.41), we can say ADMA is valued slightly cheaper.
Industry RankSector Rank
PE 17.53
Fwd PE 10.8
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 94.72% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, ADMA is valued cheaper than 90.80% of the companies in the same industry.
Industry RankSector Rank
P/FCF 91.09
EV/EBITDA 12.48
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • ADMA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ADMA has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ADMA's earnings are expected to grow with 40.03% in the coming years.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y43.82%
EPS Next 3Y40.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADMA Dividend Analysis

5.1 Amount

  • ADMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMA Fundamentals: All Metrics, Ratios and Statistics

ADMA BIOLOGICS INC

NASDAQ:ADMA (5/1/2026, 8:08:31 PM)

Premarket: 10.63 +0.11 (+1.05%)

10.52

+0.27 (+2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.04
Industry Growth13.66
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners93.43%
Inst Owner Change-1.88%
Ins Owners2.43%
Ins Owner Change1.18%
Market Cap2.51B
Revenue(TTM)510.17M
Net Income(TTM)146.93M
Analysts80
Price Target23.12 (119.77%)
Short Float %8.44%
Short Ratio2.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.01%
Min EPS beat(2)-1.96%
Max EPS beat(2)5.99%
EPS beat(4)1
Avg EPS beat(4)-7.27%
Min EPS beat(4)-31.17%
Max EPS beat(4)5.99%
EPS beat(8)4
Avg EPS beat(8)9.68%
EPS beat(12)6
Avg EPS beat(12)-7.7%
EPS beat(16)8
Avg EPS beat(16)-5.55%
Revenue beat(2)1
Avg Revenue beat(2)-0.66%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)0.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.78%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)0.81%
Revenue beat(8)5
Avg Revenue beat(8)3.94%
Revenue beat(12)9
Avg Revenue beat(12)4.07%
Revenue beat(16)13
Avg Revenue beat(16)4.88%
PT rev (1m)-11.69%
PT rev (3m)-11.69%
EPS NQ rev (1m)0.86%
EPS NQ rev (3m)3.51%
EPS NY rev (1m)5.52%
EPS NY rev (3m)6.7%
Revenue NQ rev (1m)-0.63%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.57%
Valuation
Industry RankSector Rank
PE 17.53
Fwd PE 10.8
P/S 4.91
P/FCF 91.09
P/OCF 49.72
P/B 5.25
P/tB 5.3
EV/EBITDA 12.48
EPS(TTM)0.6
EY5.7%
EPS(NY)0.97
Fwd EY9.26%
FCF(TTM)0.12
FCFY1.1%
OCF(TTM)0.21
OCFY2.01%
SpS2.14
BVpS2
TBVpS1.99
PEG (NY)0.28
PEG (5Y)N/A
Graham Number5.2016 (-50.56%)
Profitability
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROCE 34.51%
ROIC 27.76%
ROICexc 32.97%
ROICexgc 33.27%
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
FCFM 5.39%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ROICexc(3y)25.15%
ROICexc(5y)N/A
ROICexgc(3y)25.44%
ROICexgc(5y)N/A
ROCE(3y)25.11%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
F-Score6
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Debt/EBITDA 0.35
Cap/Depr 282.75%
Cap/Sales 4.49%
Interest Coverage 21.09
Cash Conversion 25.26%
Profit Quality 18.72%
Current Ratio 6.71
Quick Ratio 3.74
Altman-Z 12.46
F-Score6
WACC9.58%
ROIC/WACC2.9
Cap/Depr(3y)149.71%
Cap/Depr(5y)178.08%
Cap/Sales(3y)2.81%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y62.35%
EPS Next 2Y43.82%
EPS Next 3Y40.03%
EPS Next 5Y33.88%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%
Revenue Next Year24.85%
Revenue Next 2Y23.47%
Revenue Next 3Y22.77%
Revenue Next 5Y19.04%
EBIT growth 1Y37.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.51%
EBIT Next 3Y44.53%
EBIT Next 5Y33.81%
FCF growth 1Y-75.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.53%
OCF growth 3YN/A
OCF growth 5YN/A

ADMA BIOLOGICS INC / ADMA Fundamental Analysis FAQ

What is the fundamental rating for ADMA stock?

ChartMill assigns a fundamental rating of 6 / 10 to ADMA.


What is the valuation status for ADMA stock?

ChartMill assigns a valuation rating of 8 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.


Can you provide the profitability details for ADMA BIOLOGICS INC?

ADMA BIOLOGICS INC (ADMA) has a profitability rating of 7 / 10.


What is the valuation of ADMA BIOLOGICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 17.53 and the Price/Book (PB) ratio is 5.25.


How financially healthy is ADMA BIOLOGICS INC?

The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.